You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

NOCDURNA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nocdurna patents expire, and what generic alternatives are available?

Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and thirty-six patent family members in thirty-four countries.

The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nocdurna

A generic version of NOCDURNA was approved as desmopressin acetate by MEITHEAL on October 15th, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NOCDURNA?
  • What are the global sales for NOCDURNA?
  • What is Average Wholesale Price for NOCDURNA?
Drug patent expirations by year for NOCDURNA
Drug Prices for NOCDURNA

See drug prices for NOCDURNA

Recent Clinical Trials for NOCDURNA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ferring PharmaceuticalsPhase 2

See all NOCDURNA clinical trials

US Patents and Regulatory Information for NOCDURNA

NOCDURNA is protected by six US patents.

Patents protecting NOCDURNA

Methods comprising desmopressin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Methods comprising desmopressin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Orodispersible dosage forms of desmopressin acetate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Methods comprising desmopressin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Methods comprising desmopressin
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NOCDURNA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 ⤷  Sign Up ⤷  Sign Up
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for NOCDURNA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2712622 LUC00015 Luxembourg ⤷  Sign Up PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
2712622 122017000006 Germany ⤷  Sign Up PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249 2019C/520 Belgium ⤷  Sign Up PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622 PA2017001,C2712622 Lithuania ⤷  Sign Up PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
2712622 C02712622/01 Switzerland ⤷  Sign Up PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
2712622 PA2017001 Lithuania ⤷  Sign Up PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.